Ovarian cancer future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Mahshid |
Hudakarman (talk | contribs) No edit summary |
||
Line 4: | Line 4: | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How to Edit a Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How to Edit a Page|here]] to learn about editing. | ||
*Epithelial ovarian cancer patients can have better prognosis and outcome with some under trial Medications that believed to be promising in the future | |||
*Examples of the mechanism of action of these promising drugs are: | |||
**Targeting the angiogenesis | |||
**Targeting (inhibit) DNA repair | |||
**Targeting cell cycle | |||
**Targeting signaling pathways | |||
**Immunotherapeutic medications | |||
== References == | == References == |
Revision as of 13:17, 12 July 2019
Ovarian cancer Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Ovarian cancer future or investigational therapies On the Web |
American Roentgen Ray Society Images of Ovarian cancer future or investigational therapies |
Ovarian cancer future or investigational therapies in the news |
Risk calculators and risk factors for Ovarian cancer future or investigational therapies |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
- Epithelial ovarian cancer patients can have better prognosis and outcome with some under trial Medications that believed to be promising in the future
- Examples of the mechanism of action of these promising drugs are:
- Targeting the angiogenesis
- Targeting (inhibit) DNA repair
- Targeting cell cycle
- Targeting signaling pathways
- Immunotherapeutic medications